Company Analysis
Sign in

Amgen Inc. (AMGN)

Nasdaq: AMGN · Biological Products, (No Diagnostic Substances) · Thousand Oaks, CA · filing with the SEC since 1994
Full chart Alerts Compare
Grade6.8
◀ Past 7.1● Present 7.7▶ Future 5.2
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

3,017 patents granted to the 31 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Amgen Inc.’s names, not what it holds today.

Patents granted
3,017
2,916 utility, 93 design, 8 reissue, 1976 to Dec 31, 2025
Granted in 2025
177
Against 134 in 2024 and 117 in 2023
Applications published
3,369
202 of them in 2025
Names they are printed under
31
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals243
Medical technology141
Biotechnology98
Organic fine chemistry93
Measurement25
Computer technology8
Chemical engineering6
Analysis of biological materials5
Audio-visual technology4
Optics2
Electrical machinery, apparatus, energy1
Digital communication1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name31 counted
Amgen Inc. its own name
US, as the owner printed on each patent. 4 more under the same name are not counted (printed in CA)
1,983 granted
1,468 published
AMGEN INC. its own name
named as the applicant on its applications, in US
0 granted
913 published
IMMUNEX CORPORATION a subsidiary
US, as the owner printed on each patent
447 granted
238 published
CHEMOCENTRYX, INC. a subsidiary
US, as the owner printed on each patent
215 granted
115 published
Five Prime Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
73 granted
94 published
CHEMOCENTRYX, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
166 published
Amgen Fremont Inc. a subsidiary
US, as the owner printed on each patent
74 granted
36 published
Onyx Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
50 granted
31 published
Onyx Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
59 granted
15 published
AMGEN RESEARCH (MUNICH) GMBH a subsidiary
DE, as the owner printed on each patent
57 granted
16 published
AMGEN RESEARCH (MUNICH) GMBH a subsidiary
named as the applicant on its applications, in DE
0 granted
65 published
Five Prime Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
39 published
TeneoBio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
38 published
Onyx Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
33 published
Horizon Therapeutics Ireland DAC a subsidiary
named as the applicant on its applications, in IE
0 granted
21 published
Viela Bio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
21 published
Amgen Fremont Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
15 published
Viela Bio, Inc. a subsidiary
US, as the owner printed on each patent
8 granted
7 published
Amgen Canada Inc. a subsidiary
CA, as the owner printed on each patent
13 granted
1 published
TeneoBio, Inc. a subsidiary
US, as the owner printed on each patent
10 granted
3 published
Horizon Therapeutics Ireland DAC a subsidiary
IE, as the owner printed on each patent
8 granted
3 published
Horizon Therapeutics USA, Inc. a subsidiary
US, as the owner printed on each patent
9 granted
2 published
Amgen SF, LLC a subsidiary
US, as the owner printed on each patent
5 granted
4 published
Horizon Therapeutics USA, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
9 published
AMGEN K-A, INC. a subsidiary
US, as the owner printed on each patent
5 granted
0 published
Amgen K-A, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
IMMUNEX CORPORATION a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
ONYX PHARMACEUTICALS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
4 published
AMGEN (EUROPE) GMBH a subsidiary
CH, as the owner printed on each patent
1 granted
0 published
AMGEN (EUROPE) GMBH a subsidiary
named as the applicant on its applications, in CH
0 granted
1 published
AMGEN INC., a Delaware Corporation its own name
US, as the owner printed on each patent
0 granted
1 published
Names not counted (5)
Horizon Therapeutics Limited
Most of its patents print US; this name counts in IE. 0 granted and 41 published under it are not counted.
Horizon Therapeutics Limited
Most of its patents print US; this name counts in IE. 20 granted and 9 published under it are not counted.
BioVex LLC
Most of its patents print GB; this name counts in US. 16 granted and 11 published under it are not counted.
AMGEN INC
No country is printed for it. 0 granted and 14 published under it are not counted.
BioVex LLC
Most of its patents print GB; this name counts in US. 0 granted and 3 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,442KIF18A inhibitorsOrganic fine chemistryAmgen Inc.
Dec 23, 202512,503,700Control of total afucosylated glycoforms of antibodies produced in cell cultureBiotechnologyAmgen Inc.
Dec 16, 2025D1,106,445Handheld drug delivery deviceAmgen Inc.
Dec 16, 202512,497,666Nucleic acid biomarker and use thereofPharmaceuticalsAmgen Inc.
Dec 16, 202512,497,383Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesOrganic fine chemistryCHEMOCENTRYX, INC.
Dec 16, 202512,496,331Combination therapies of prednisone and uricase molecules and uses thereofPharmaceuticalsHorizon Therapeutics USA, Inc.
Dec 16, 202512,495,776Transgenic non-human animals producing modified heavy chain-only antibodiesBiotechnologyTeneoBio, Inc.
Dec 9, 202512,493,943Apparatuses, systems and methods for plunger-stopper depth measurement in pre-filled syringesMedical technologyAmgen Inc.
Dec 9, 202512,493,019Methods of determining protein stabilityMeasurementAmgen Inc.
Dec 2, 202512,485,219Drug delivery devices with partial drug delivery member retractionMedical technologyAmgen Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388670CONTINUOUS MANUFACTURING PROCESS FOR BISPECIFIC ANTIBODY PRODUCTSBiotechnologyAMGEN INC.
Dec 25, 20252025/0388579SYNTHESIS OF KRAS G12C INHIBITOR COMPOUNDOrganic fine chemistryAmgen Inc.
Dec 25, 20252025/0388574HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USEOrganic fine chemistryAMGEN INC.
Dec 18, 20252025/0382080Predicting Machine Parameters to Achieve Target Syringe Plunger Depth PlacementMedical technologyAMGEN INC.
Dec 18, 20252025/0381187KRAS G12C INHIBITORS AND METHODS OF USING THE SAMEOrganic fine chemistryAmgen Inc.
Dec 11, 20252025/0376529METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTSPharmaceuticalsAmgen Inc.
Dec 11, 20252025/0375452SOTORASIB DOSING REGIMENPharmaceuticalsAmgen Inc.
Dec 11, 20252025/0375385CAPSULE FORMULATIONSPharmaceuticalsCHEMOCENTRYX, INC.
Dec 4, 20252025/0368737LOW PH PHARMACEUTICAL COMPOSITION COMPRISING T CELL ENGAGING ANTIBODY CONSTRUCTSPharmaceuticalsAMGEN INC.
Dec 4, 20252025/0368643SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUNDOrganic fine chemistryAmgen Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 144 · Biotechnology 93 · Medical technology 66 · Organic fine chemistry 51 · Measurement 22 · Computer technology 16.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AMGN · research, not advice